Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Bristol/AstraZeneca In Driver’s Seat, GLP-1 Race Takes A Turn

Executive Summary

Bristol-Myers and AstraZeneca’s acquisition of Amylin as part of a 50-50 collaboration brings a big new player into the fast-growing GLP-1 class, which is emerging as a key component of treatment in the large, but highly competitive Type 2 diabetes market.

You may also be interested in...

GSK’s Tanzeum Once-Weekly GLP-1 To Launch In Third Quarter

FDA requires post-marketing studies to identify any cases of medullary thyroid cancer related to the drug and evaluate cardiovascular risk; GSK touts Tanzeum’s sustained glycemic effect, tolerability and its potential use as an alternative to insulin.

Repurposing Leptin: How a “Fat Drug” Became a Model for a Leaner Industry

Two decades ago, the “fat dissolving” protein leptin was touted as one of the biggest opportunities in biotech—based on preclinical rodent studies. The compound may finally be making it to market in a very different model: as an orphan drug sponsored by Big Pharma.

On The Wings Of Lantus: Sanofi Sees Clearer Skies Ahead In Diabetes

With the removal of a near-term competitive threat to Sanofi’s hallmark insulin franchise, 2013 is poised to be a momentum-building year for the big pharma, and more specifically, its diabetes business. The opportunity can’t come too soon, as the company launches the GLP-1 agonist Lyxumia into a crowded and fiercely competitive field.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts